Business Context and Reporting Period
Company: Apimeds Pharmaceuticals US, Inc. (Apimeds)
Filing Type: Form 8-K (Current Report)
Date of Report: December 1, 2025
Event: Completion of a business combination (Merger) with MindWave Innovations Inc. (the "Company") and entry into a material definitive agreement. Apimeds (Acquiror) merged with a subsidiary of MindWave, resulting in MindWave becoming a wholly-owned subsidiary of Apimeds. The transaction effectively changes control of the registrant.
Key Financial Metrics and Transaction Consideration
Transaction Consideration: Existing stockholders of MindWave received a mix of Apimeds Common Stock and Series A Convertible Preferred Stock.
- Common Stock Allocation: Represents 29.9% of total Apimeds Common Stock outstanding immediately post-closing.
- Preferred Stock Allocation: Represents 61% of total equity on an as-converted, fully diluted basis (excluding the common stock issued above).
- Total Equity Stake: MindWave stockholders collectively hold 90.9% of Apimeds' equity capital on an as-converted, fully diluted basis.
Debt and Financing:
- Convertible Notes: Apimeds entered a Securities Purchase Agreement for senior convertible notes up to $120,900,000 at an 8% original issue discount.
- Initial Funding: $10,875,000 available at closing; $2,175,000 upon effectiveness of resale registration.
- Additional Capacity: Investor has discretion to purchase up to $13,075,000 in additional notes.
- Terms: 12-month maturity; 0% interest unless default occurs; convertible at 80% of the lowest 5-day VWAP.
Liquidity and Cash Flow: The filing does not provide specific cash balance or operating cash flow figures for the reporting period. Liquidity is expected to be supported by the initial note funding and a planned private placement offering of up to $120,900,000.
Material Changes Versus Prior Period
- Corporate Structure: MindWave Innovations Inc. is now a direct wholly-owned subsidiary of Apimeds.
- Capital Structure: Issuance of 7,263,865 shares of Series A Convertible Preferred Stock and significant dilution via the Merger Consideration.
- Debt Load: Creation of a new senior unsecured debt obligation of up to $120.9 million.
- Stock Split: A 1-for-10 reverse stock split of Apimeds Common Stock was approved via written consent.
- Management: Erik Emerson resigned as CEO and was appointed President. Dr. Vin Menon was appointed CEO. Two new directors (Dr. Vin Menon and Amir Dossal) were appointed to the Board.
- Asset Transfer: Apimeds' existing assets and liabilities (the "Bio Business," focused on Apitox) are to be transferred to a new subsidiary, Lokahi Therapeutics, Inc. ("Bio Sub"), within five business days of closing.
Guidance, Outlook, and Risks
Management Commentary and Outlook:
- Financing Goals: Management intends to consummate a private placement offering of up to $120,900,000.
- Operational Focus: The Bio Business (Apitox development) will be preserved and operated by Bio Sub for at least six months post-closing or until $14.8 million is raised for that entity.
- Future Actions: Automatic conversion of Series A Preferred Stock to Common Stock is scheduled to occur after listing approvals and stockholder consents are finalized.
Risks and Contingencies:
- Listing Approval: The transaction and subsequent conversions depend on NYSE American listing approvals.
- Financing Execution: Risk of inability to consummate planned financings on acceptable terms or within expected timeframes.
- Bitcoin Volatility: The filing notes risks related to volatility in bitcoin markets impacting collateral requirements (referencing prior bitcoin assets).
- Integration: Risks associated with integrating businesses, retaining key personnel, and realizing synergies.
- Debt Covenants: The Notes include negative and affirmative covenants; failure to meet registration deadlines for the Notes results in liquidated damages.
Investor Verification Checklist
- Information Statement: Verify the definitive Information Statement (Schedule 14C) once filed with the SEC for full details on the Written Consent and Proposals.
- Pro Forma Financials: Await the amendment to this 8-K (due within 71 days) for required pro forma financial information and unaudited interim financial statements of MindWave.
- Listing Status: Confirm NYSE American's approval of the listing application and the Reverse Stock Split.
- Financing Progress: Monitor the status of the $120.9 million private placement offering and the effectiveness of the resale registration statement for the Convertible Notes.
- Asset Transfer: Confirm the transfer of Apimeds' existing Bio Business assets to Lokahi Therapeutics, Inc. (Bio Sub).
- Warrant Issuance: Note the issuance of a warrant to E.F. Hutton & Co. LLC for 712,880 shares (exercise price not specified in text).